Drugs / MAB-22
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06310824 | Jun 2024 → Jul 2025 | — | Xentria, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06504966 | Oct 2025 → Oct 2027 | osteoporosis | Xentria, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAB-22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06310824 ↗ |
| Route | Subcutaneous | “single subcutaneous injection” NCT06310824 ↗ |